The WisdomTree US MidCap Dividend Fund (DON) offers diversified mid-cap value exposure with a 2.3% yield and monthly dividends but has underperformed its benchmark and peer ETFs like IMCV, REGL, and VOE in both total and risk-adjusted returns. Although DON's focus on dividend growth and value stocks is appealing, its higher expense ratio and lagging performance reduce its attractiveness. Analyst Fred Piard maintains a Hold rating on DON, suggesting investors consider alternative mid-cap value ETFs that provide better risk-return profiles and lower fees. This update reflects data and outlook as of September 2024.
The WisdomTree US MidCap Dividend Fund (DON) is discussed here with data context from Pluang as of Oct 14, 2026 21:41 WIB. For readers following US stocks on Pluang, out of 150 priced stocks, 38 rose and 111 fell today. Notable movers include HPE at USD 65.58 with a 1-day change of -4.68% and Pluang order activity of 89% Sell / 11% Buy, MRVL at USD 256.69 down 4.48%, and JBLU at USD 3.20 down 4.48% but with 100% Buy activity. The most notable figure is the heavy sell activity on HPE shares.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
